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Abstract
Topical medication remains the first line treatment of glaucoma; however, sustained ocular drug delivery via topical
administration is difficult to achieve. Most drugs have poor penetration due to the multiple physiological barriers of the eye
and are rapidly cleared if applied topically. Currently, daily topical administration for lowering the intra-ocular pressure (IOP),
has many limitations, such as poor patient compliance and ocular allergy from repeated drug administration. Poor
compliance leads to suboptimal control of IOP and disease progression with eventual blindness. The delivery of drugs in a
sustained manner could provide the patient with a more attractive alternative by providing optimal therapeutic dosing,
with minimal local toxicity and inconvenience. To investigate this, we incorporated latanoprost into LUVs (large unilamellar
vesicles) derived from the liposome of DPPC (di-palmitoyl-phosphatidyl-choline) by the film hydration technique. Relatively
high amounts of drug could be incorporated into this vesicle, and the drug resides predominantly in the bilayer. Vesicle
stability monitored by size measurement and DSC (differential scanning calorimetry) analysis showed that formulations with
a drug/lipid mole ratio of about 10% have good physical stability during storage and release. This formulation
demonstrated sustained release of latanoprost in vitro, and then tested for efficacy in 23 rabbits. Subconjunctival injection
and topical eye drop administration of the latanoprost/liposomal formulation were compared with conventional daily
administration of latanoprost eye drops. The IOP lowering effect with a single subconjunctival injection was shown to be
sustained for up to 50 days, and the extent of IOP lowering was comparable to daily eye drop administration. Toxicity and
localized inflammation were not observed in any treatment groups. We believe that this is the first demonstration, in vivo, of
sustained delivery to the anterior segment of the eye that is safe and efficacious for 50 days.
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Introduction
Glaucoma is the second leading cause of blindness in the world
[1]. Intraocular pressure (IOP) is the main, modifiable risk factor
for this disease. Drugs to treat IOP are classified by the mode of
action of the active ingredient eg. prostaglandin analogs, beta
blockers, alpha agonists and carbonic anhydrase inhibitors [2]. In
addition, fixed combination drugs are now available for patients
who require more than one type of medication. Currently,
medications used to lower IOP are applied topically, which have
poor ocular bioavailability, side effects associated with chronic use
(allergic conjunctivitis and dry eyes) and require patient reliance
on daily administration [3–8]. Since glaucoma requires life-long
treatment, drug delivery for glaucoma remains a challenging
problem, as currently only eye drops are available for topical drug
delivery which is associated with very variable therapeutic efficacy
and also heavily dependent on patient compliance.
One of the main barriers to ocular drug delivery is the corneal
epithelium. It is a tri-lamellate structure consisting of a hydrophilic
rigid stromal layer of cells sandwiched between two lipophilic
(epithelium and endothelium) layer of cells [9,10]. Of the two
common pathways (paracellular and transcellular) that have been
proposed for the transport of drug molecules, the drug molecules
would predominantly use the transcellular path to cross the
cornea, where the lipophilicity and pKa are the major parameters
that decide the entry of drug molecules [9]. However, in addition
to the permeation obstacles, the tear drainage also causes any
topically applied drug to get washed away fairly rapidly. Because
of all these factors, a mere 5% of the free drug applied on the
corneal epithelium successfully penetrates through the cornea. In
order to improve bioavailability of drug, the transport barrier as
well as prolonging the retention of the drug carrier in the anterior
segment of the eye needs to be achieved.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24513Latanoprost, a lipophilic drug molecule is usually effective for
reducing the IOP. Latanoprost is an isopropyl ester of its
corresponding acid, which is the active constituent. In the eye, it
is expected that the ester is hydrolyzed into IPA (isopropyl alcohol)
and latanoprost acid [11]. The latanoprost acid has an aqueous
solubility of 5 mg/ml [12]. However, the latanoprost acid
experiences a higher penetration resistance through the lipophilic
epithelium and the endothelial cells of the corneal membrane.
Latanoprost is usually delivered in the form of either an oil/water
emulsion (XalatanH), or lipid/buffer emulsion [11,13]. There is
another unavoidable issue of irreversible yellow pigmentation of
corneal epithelium after regular application of commercial eye
drop for longer period (beyond three months). This pigmentation
is attributed to the presence of benzalkonium chloride (which acts
as a preservative for latanoprost in this formulation).
Therefore, to circumvent these critical issues of (i) frequent
instillations for required efficacy, (ii) drug stability/clearance and
(iii) undesirable side effects of drug, several delivery vehicles have
been studied in the literature [14]. Of the carriers proposed,
liposomes were thought to be the most promising [15–17], to
overcome these challenges for higher therapeutic efficacy and
sustained release.
Liposomes are versatile vehicles for incorporation of both
hydrophilic and lipophilic drug molecules, due to its physical
structure with a polar core and a lipophilic bilayer. Liposomal
encapsulation also protects drug molecules from enzymatic
hydrolysis in the physiological environment. However, the size
of small uni-lamellar vesicle (SUV, 20–50 nm) or large uni-
lamellar vesicle (LUV, ,100 nm) often restricts its transport
through epithelial layers, and also permits rapid clearance during
topical administration. Thus, several modifications of liposomes
have been reported: (i) surface modification with charged lipids
which can make vesicles adhere to the oppositely (negatively)
charged corneal epithelium, (ii) increasing the lipophilicity of the
drug molecules, and (iii) modifying the integrity of corneal
epithelium transiently by using a penetration enhancer. Such
modifications would facilitate the first stage of the entry of drug
molecules, while the subsequent permeation would be governed
by pKa, hydrophilicity/lipophilicity of the drug molecules
[10,18].
A review report by Meisner and Mezei [19] compared various
routes of administration (e.g. topical administration, intravitreal,
subconjunctival and systemic injection) of liposomal formulations.
The first successful application of topically applied drug-loaded
liposome (MLVs) formulation was carried out in the rabbit eye by
Smolin et al [20]. In a separate study, Schaeffer and Krohn [21]
have shown that the order of liposomal uptake by the corneal
epithelium varied as follows: MLV+ (MLVs with positively
charged lipid).SUV+ (SUVs with positively charged li-
pid)&MLV2 (MLVs with negatively charged lipid.SUV2
(SUVs with negatively charged lipids).MLV=SUV. However,
the overall permeation of a water soluble drug, penicillin G, was
highest for SUV+ and was minimal for MLVs and free drugs, due
to the large surface area of SUVs. Delivery of a hydrophobic drug
due to its low water solubility limit is considerably more
challenging. The limited bilayer space availability in the lipid
bilayer often limits the loading of a lipophilic drug and is the most
significant hurdle in developing liposomes for sustained delivery of
hydrophobic entities, including latanoprost.
Lin et al [22] found that in vitro application of norfloxacin
loaded liposome onto cornea showed improved drug retention
when compared to free drug solution. They indicated a probable
corneal endocytic uptake of norfloxacin loaded liposome through
the corneal membrane. There appears to be no other report of
enhanced drug retention in the anterior segment of the eye. The
pharmacokinetics of drug release from the liposome vesicle and
penetration through corneal epithelium is still poorly understood.
If the drug release from these vehicles is appreciably slow, then
clearance will dominate drug adsorption and diffusion through
corneal epithelium [23]. Therefore, released drug will be too
diluted (tear dilution) to have an adequate gradient to cross the
corneal epithelium [24]. Thus, it may perform poorer than even
free drug.
There are very few successful in vivo studies reported for
topically applied liposome loaded drug formulations. Hathout et al
have shown that positively charged egg phosphatidyl choline (PC):
cholesterol (CH): stearyl amine (7:4:1) multilamellar vesicles
(MLVs) loaded with acetazolamide, when applied topically, shows
the highest lowering of IOP (27.8 mm Hg) after 3 hrs. However
this lowering lasts only for about 8 hours [25]. Hirnle et al have
compared sub-conjunctival delivery of 6-carboxyfluorescein (as a
‘‘model’’ drug) in rabbit eyes in aqueous solution and liposomal
formulation. The released drug concentration was noticeably high
after 30 min and transitory conjunctivitis (common swelling due to
excess drug concentration) was observed, but no side effect was
reported. The liposomal formulation showed detectable levels of
carboxyfluorescein at the injection site of sub-conjunctiva along
with sclera, cornea, choroid and retina after 7 days of injection,
but the reason for the 7 day sustainability/retention in this study
was not clearly understood [26].
Although liposomal carriers have been evaluated for delivery of
drugs topically on the front of the eye, none have been successful
to date for sustained release. Very few studies have been reported
on the fate of liposomes injected subconjunctivally. Nevertheless,
subconjunctival injection may be an attractive option for sustained
delivery of anti-glaucoma agents, provided the effects can be
sustained for at least 1 month, preferably longer. Specifically, for
the delivery of latanoprost (a prostaglandin derivative that is
currently administered via once-a-day eye drops), there is no
report on comparison of in vitro and in vivo release behavior. In
this work, we have evaluated liposomal formulations based on
dipalmitoylphosphatidylcholine (DPPC). DPPC lipids have satu-
rated acyl chains and are expected to remain stable in vivo. In the
present report, we have evaluated carrier stability, drug partition-
ing, in vitro drug release, toxicity, efficacy and sustainability of
latanoprost-incorporated DPPC liposomes upon subconjunctival
administration in rabbit eyes.
Materials and Methods
1.1. Materials
DPPC was purchased from NOF Corporation, Japan. Cellulose
ester dialysis bags (16 mm dia610 m flat width) were obtained
from Spectrum labs, USA. Polycarbonate filter membranes of sizes
(0.2, 0.1 and 0.08 mm) and drain discs were purchased from
Northern Lipids Inc, Canada. Chemicals for phospholipid analysis
such as ammonium thiocyanate and ferric chloride hexahydrate
were purchased from Sigma, USA. Sodium phosphate dibasic
anhydrous (Na2HPO4), Potassium phosphate monobasic anhy-
drous (KH2PO4), Potassium chloride (KCl), Sodium chloride
(NaCl) salts were purchased from Sigma, USA and used without
further purification. Latanoprost was purchased from Chemical
Testing and Calibration Laboratories, China. The water used in
all the experiments was from MiliQ purification system with a
resistivity of at least 18.260.2 mV-cm. All solvents for drug
estimation was carried out using high performance liquid
chromatograph (HPLC) grade (.99% purity) and were purchased
from Tedia, USA.
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Latanoprost loaded liposomes were formulated by thin film
hydration technique as described elsewhere [27]. Briefly, known
amount of DPPC (lipid concentration, 15 mM) was weighed and
dissolved in chloroform: methanol (2:1, v/v) solvent mixture. A
known amount of drug dissolved in acetonitrile (ACN) was added
to this mixture and maintained in a 40uC water bath. The
drug:lipid mole ratios were varied between 0.04 to 0.24. Solvents
were removed from the round bottom flask using a rotary
evaporator (IKA RV 10, Germany) maintained in a 40uC water
bath (IKA MB 10 basic, Germany). A thin dry drug loaded lipid
film was obtained and to this film, isotonic PBS (150 mM, pH 5.5)
buffer was added and sonicated for 3–5 min, to form multilamellar
vesicles (MLVs). We avoided a longer exposure time to ultrasound,
due to possibilities of increased lipid oxidation and/or drug
leakages as reported elsewhere [28]. After the completion of the
sonication step, the resulting formulations were extruded 10–15
times sequentially through polycarbonate filters of size (0.2 mm/
0.1 mm/0.08 mm), fitted in a bench top extruder (Northern Lipids
Inc, Canada). This will result in formation of LUVs with a size
distribution of 0.09–0.12 mm. All the above-mentioned steps were
performed under aseptic conditions. All glassware, PBS (filtered
through 0.2 mm filter) solution were sterilized by autoclaving, and
the entire procedure was performed under a laminar flow hood
(Esco, Singapore). Sterility (Method suitability test and Sterility
test) conditions of the drug loaded formulations were verified
through an external agency (BRASS, Biomedical Research and
Support Service Pvt. Ltd., Singapore) and found to meet the
desired criteria.
1.3. In Vivo Study in Rabbits
1.3.1. Topical application of liposomal formulation as eye
drop. Six female New Zealand white rabbits were divided into
two treatment groups. Daily IOP values were monitored and a
stable IOP baseline value was observed by the end of seven days.
One treatment group (3 rabbits, 6 eyes) received one daily drop of
liposomal formulation and the other treatment group received a
drop of XalatanH formulation (3 rabbits, 6 eyes).
1.3.2. Subconjunctival delivery of latanoprost loaded
liposomes. Twenty three female New Zealand White rabbits
(both eyes, BE=46 eyes) were used in this study. The baseline IOP
was measured twice daily using a calibrated Tono-pen XL for 7
days in all rabbits. The rabbits were divided into 3 treatment
groups: (i) Group A (8 rabbits, 16 eyes) received 1 eye drop of
topical latanoprost daily; (ii) group B (8 rabbits, 16 eyes) received 1
subconjunctival injection of latanoprost-loaded liposomes and (iii)
group C (7 rabbits, 14 eyes) received subconjunctival injection of
liposomes only (with no drug). Rabbit eyes in groups B and C
received a subconjunctival injection of liposomes at day 0 and at
day 50 using 27 gauge sterile needles, since the IOP returned to
the baseline values. All procedures were performed under topical
anesthesia (amethocaine 2.5%) by a single surgeon (MA). In brief,
the eye was cleaned with 50% povidone iodine and 0.1 ml of
liposome was injected in the subconjunctival space in the superior
temporal region of each eye. Topical chloramphenicol 2.5% was
administered to the operated eye daily for 5 days. We obtained
approval from the SingHealth Institute Animal Care and Use
Committee and all procedures were performed in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research.
1.3.3. Clinical evaluation. Twice-daily IOP measurements
were conducted using a calibrated Tono-pen XL and visual
inspection of all eyesfor clinical signs of inflammationinthe eyeand
at the injection site and for any evidence of infection. Slit-lamp
examination of the exterior and anterior chamber of the eyes was
done prior to injections and weekly thereafter. Anterior segment
photographs and anterior segment optical coherence tomography
(AS-OCT) of the operated eyes was performed at weekly intervals.
The rabbits were also monitored for any gross changes such as eye
discharge, squinting or abnormal behavior. We used a modified
version of the Moorfields bleb grading system to objectively assess
vascularity in all eyes [29].
1.3.4. Histology. At the end of the study period (80 days) all
rabbits were sacrificed and sampled aqueous and vitreous humor
for latanoprost concentrations via HPLC analysis. Euthanasia was
carried out with intraperitoneal pentobarbitone (60–150 mg/kg)
followed by enucleation of the operated eyes. Sterile syringes with
27-gauge needles were used to sample 0.1 ml of aqueous humor
and 0.1 ml of vitreous humor before immediately immersing the
eyes in a mixture of 4% paraformaldehyde and 2.5% neutral
buffered formalin for 24 hours. The globes were dehydrated,
embedded in paraffin and sent for microtome sectioning and
respective staining (Haematoxylin and Eosin (H&E) and Sirius red
F3BA; Sigma, St. Louis, MO). Polarization microscopy of stained
collagen fibers for any gross collagen bundling patterns and a
modified semi-quantitative grading system as previously described
was used to assess fibrosis and scarring [30].
1.3.5. Statistical analysis. Statistical analysis included
descriptive statistics, where the mean and standard deviation
(SD) was calculated for the continuous variables; while frequency
distribution and percentages were used for categorical variables.
Comparisons between categorical variables were conducted by
Fisher’s exact tests, whereas the one-way analysis of variance
(ANOVA) test was used for means. A P-value,0.05 was
considered statistically significant.
1.4 Characterization of drug loaded liposome vesicles
1.4.1. Size and Zeta Potential. The average size of the
liposomes as well as the size distribution (polydispersity index, PDI)
of each formulation was estimated using the Malvern Zetasizer
Nano ZS (UK). A small aliquot of the formulation was diluted with
a large (1:100, v/v) volume of distilled water and any air drop
interference while measurement was eliminated all throughout the
measurement. Vesicle sizes were monitored following synthesis, on
storage at 4uC and after drug release. The zeta potential values
were estimated by Laser Doppler method using the same
instrument in 0.001 M PBS buffer at 25uC. DPPC lipids was
ensured that more than 75% of latanoprost was entrapped into the
liposome while measurement. As indicated in Table 1, there was
no appreciable change in particle size, zeta potential, although
entrapment efficiency was noted to be slightly higher with lower
drug/lipid mole ratio.
1.4.2. Lipid Analysis. The phospholipid concentration was
estimated using colorimetric method as described elsewhere [31].
Six point calibration was prepared for DPPC (e ¨max=525 nm)
and were later used for estimation of unknown concentration of
lipids in vesicles obtained after extrusion. The amount of
phospholipids in liposomal vesicles after extrusion was estimated
to be 80–85% (by mass) while, the remaining was considered lost
while extrusion and handling.
1.4.3. DSC Analysis of the Drug and DPPC
interaction. DSC analysis of the latanoprost loaded DPPC
liposome formulations was done using TA instruments Q10 model.
The instrument Q10 model was calibrated with Indium for the best
Cp estimate and high signal to noise ratio. Number of heating/
cooling cycles, heating rate, volume of liposome formulation, and
concentration in DI water/PBS buffer were all established by
comparing the standard DSC chromatograms available for DPPC
Sustained Latanoprost Delivery in the Rabbit Eye
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chromatograms obtained from Q10 undoubtedly needed higher
lipid mass compared to nano DSC, but the nature of DSC
chromatograms were same, and therefore was chosen for further
data interpretation. A heating rate of 1uC/min between
temperature ranges 220uCt o6 0 uC was selected to avoid any
thermal decomposition of drug molecule [33]. A third heating cycle
was always considered for all DSC analysis. The results were
reproducible for 100 mg/ml liposomal formulations and a sample
volume of 10 ul was taken in a hermitic pan for analysis. An empty
pan was used as a reference.
1.4.4. Drug concentration using High Performance Liquid
Chromatography Method. The HPLC system (Agilent series
1200) consisted of solvent degasser, high precision pump, auto
sampler, column heater, column, and a photo diode (UV) array
detector. Each unit was interfaced with computer through
Chemstation software. The chromatographic separation was
performed on reverse phase Eclipse-XDB C18 column (5 mm,
4.6 mm ID6250 mm) using mobile phase as ACN:Water at 70:30
(v/v) proportions at 1.0 ml/min flow rate and detector wavelength
was set at e ¨=210 nm. The retention time was 4.6 min and the
temperature of the column was maintained at 25uC.
The drug estimation from release medium was done directly
from the collected samples. While, the drug present in the lipid
vesicles needed a separate treatment. Lipid vesicles of drug loaded
formulation were broken by adding 1:4 volumes of IPA (isopropyl
alcohol) and the lipid mass was isolated from the rest of solution by
ultracentrifugation at 13000 rpm for 30 minutes. The supernatant
was diluted 506 times with PBS buffer to match within the
calibration limit. HPLC system was calibrated (R
2=0.998) using
known concentrations of latanoprost solution (25, 10, 7.5, 5, 2.5,
1.0, 0.1 mg/ml) by diluting latanoprost dissolved in ACN in PBS
buffer (150 mM, pH 7.4). The estimation of the total drug was
carried out by breaking the liposomal vesicles with IPA. The
broken liposomal mixture was centrifuged and the clear
supernatant was diluted with PBS buffer and estimated by HPLC.
Each sample was tested at least five times to obtain concordant
data of the total drug concentration of stock liposomal formula-
tions. Amount (%) of drug released at various time were plotted
against time.
Drug loading efficiency (%)~
100|(Amount of drug retained=drug taken initially)
1.4.5. Drug partition coefficient estimation. A lipophilic
drug such as latanoprost distributes between a lipid bilayer and the
aqueous continuous phase and the concentration ratio between
these two phases determines the partition coefficient. The values
for partition coefficient were estimated from the MLVs prior to the
extrusion step. Briefly, known sample volumes were collected in
microfuge tubes and centrifuged at 10000 rpm for 30 mins. Due
to the large size of MLVs, in the micron size ranges, we were able
to separate out the fractions of the lipid pellet and the clear
supernatant. The drug estimated from the supernatant is a
measure of continuous (buffer) phase drug concentration, while
this amount when subtracted from the total drug concentration
yields drug partitioned into the bilayer. Thus, drug partition
coefficient (P.C.) is estimated using the following expression (each
concentration in mass per unit volume):
P:C:~(Total drug-drug in buffer)=drug in buffer
Drug: Lipid ratio (D/L) is an important characteristic property
of liposomal systems. The final drug: lipid mole ratios in the
liposomal formulation obtained after extrusion were estimated as
follows:
Final drug to lipid (D/L) mole ratio=Moles of drug left/Moles
of the lipid left after extrusion.
1.4.6. Drug Release studies. In this study, the drug loaded
liposomal formulation was physically separated from the receptor
chamber by a dialysis membrane and the released drug amounts
were assayed from the release medium at various time intervals.
Briefly, 1 ml of drug loaded liposomal suspension was taken in a
cellulose ester dialysis bag (100 kD MWCO, 1.6 cm dia66c m
length) and clipped at both ends using dialysis clips. The whole
assembly was then placed in screw capped bottle (to avoid
evaporation loss during the whole duration of release study)
containing 40 ml PBS buffer (150 mM, pH 7.4: 137 mM NaCl,
2.68 mM KCl, 1.76 mM KH2PO4, 10.14 mM Na2HPO4). A
volume ratio of 1:40 (liposome:buffer) was chosen to maintain a
pseudo-sink condition for drug release. The dialysis bag was
continuously agitated in an orbital shaker (Sartorius Cartomat,
USA) maintained at 37uC at 50 rpm. Aliquots were withdrawn
from the release medium and was filtered through 0.2 mm syringe
filter and collected in amber color HPLC sample bottle (2 ml,
Agilent) followed by storage in the fridge at 4uC until they were
estimated. To obtain a closer approximation to the dynamic sink
condition in the in-vitro setup, the dialysate was completely
exchanged with fresh PBS buffer after every 24 h and the released
drug concentration in the dialysate was estimated as discussed
before. Each experiment was repeated at least 3 times. The
volume of liposomal formulation and the sizes of vesicle in the
dialysis tube were recorded at the end of the release study to check
any dilution effect of liposomal formulation and size changes of
vesicles that occurred during drug release.
Results
2.1. Drug loading Efficiency
The observed encapsulation efficiency was in the range 75–88%
for various formulations as reported in Table 1. The concentration
of loaded drug after extrusion was estimated to be 200–660 ug/ml
which is 4–12 fold higher than the XalatanH (50 ug/ml) eye drop
formulation whose normal dose requirement is one drop a day
Table 1. Size, Zeta potential and loading efficiency of latanoprost loaded DPPC Liposome after extrusion.
DPPC Liposomes
(D/L, mole/mole)
Size
(nm) PDI
Zeta potential
(mV)
Drug Loading Efficiency
(%)
0.04 90610 0.09–0.12 24.662.0 8563%
0.104 120620 0.1–0.2 27.162.2 8065%
doi:10.1371/journal.pone.0024513.t001
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higher than the initial value, which indicates that there is more
partial loss (,20%) of lipid molecules than of drug molecules in
the various stages of size reduction. These mole ratios are much
higher than the values obtained for a comparable lipophilic drug,
ibuprofen, in the cholesterol-containing lipid vesicle of Mo-
hammed et al [35]. The estimated mole ratios of drug/lipid were
in the range between 0.04–0.37 (Table 2). The highest drug/lipid
mole ratio we obtained was nearly 3–5 times higher than earlier
reported ibuprofen loading by Mohammed et al [35] or Cisplatin
by Perez-Soler and Khokhar [36]. However, this very high loading
of latanoprost did not affect much on the vesicle stability (LUVs).
2.2. In vitro size stability
The size measurements at various time intervals eg. W0 (initial),
W2 (two weeks later), W4 (four weeks later) were carried out using
the Zetasizer. From Table 3, it is seen that vesicles are reasonably
stable whilestoredat 4uCaslongasthedrug/lipidratio islow.Effect
of vesicle destabilization was noted when the drug/lipid mole ratio
exceeded 0.1. This was expected since the high loading would
disrupt the structure ofthe bilayer, with shape distortion, asreported
from another lipophilic drug in a similar vesicle [37]. Figure 1 shows
the sizes after 12 weeks ofstorage of drug-loaded vesicles at 4uC, and
it is evident that the larger loading leads to greater size changes (all
the vesicles start out at roughly the same size).
2.3. Drug release behavior
Latanoprost release behavior from loaded liposomal formula-
tions varying in drug/lipid mole ratio, is expressed in terms of
cumulative drug release (%) (Figure 2). In order to better mimic
the in vivo release condition, the buffer solution was exchanged
every 24 h with fresh PBS pH 7.4 maintained at 37uC. The
release rate of any formulation increases with the initial drug
concentration. There is no appreciable change between drug/lipid
mole ratios 0.04 to 0.11, but, beyond this limit the rate increases.
For a better understanding of the release pattern, vesicle sizes
were recorded at the end of every release study (Table 3). For
molar ratios lesser than drug/lipid mole ratio of 0.14, the relative
size variation is negligibly small; however, with higher amounts of
drug, the size variations and polydispersity were higher, indicating
probable vesicle destabilization during release, thus leading to
faster drug release. As discussed in the stability section, the higher
drug concentrations in the bilayer might affect the vesicle stability
and thus accelerate drug release. Further understanding comes
from estimation of thermal stability of drug loaded DPPC lipid
bilayer using differential scanning calorimetry (DSC) measure-
ments.
2.4. DSC analysis
Figure 3 shows the DSC thermograms of different latanoprost
loaded DPPC liposome. The DSC shows endothermic transition
for both drug-free and drug-loaded liposome. Plain DPPC
liposome shows a sharp main transition (41.1uC) with an expected
pre transition at (35uC) as well. As the drug/lipid mole ratio is
increased, the pre transition disappears and the endothermic main
transition broadens and shifts (Figure 3). It is also interesting to
note the shift is towards a higher temperature as the drug/lipid
mole ratio changes from 0 to 0.086 (41.1 to 47uC). The trend then
reverses and shifts towards lower temperature, although with a
considerable peak broadening. With higher drug amount (drug/
lipid mole ratio of 0.114) the transition disappears completely.
This observed effect could be an indication of the gradual change
from more ordered liquid to more disordered liquid behavior,
caused by excessive drug incorporation. The peak broadening with
latanoprost incorporation resembles the trend reported for
cholesterol in DPPC lipid bilayer [38].
The lipophilic latanoprost molecules would preferentially locate
themselves in the lipid bilayer, and thus might influence the
stability of the bilayer. Excess drug loading may affect stability of
vesicles, which could yield a ‘‘leakier’’ liposome and thus faster
release.
2.5. Partition coefficient of latanoprost in DPPC liposome
The ratio of drug concentration in the lipid bilayer to that in the
continuous phase is defined as partition coefficient (P.C.), as
discussed earlier. As shown in Figure 4, a decrease in partition
coefficient from 11.061 to 6.061 was observed upon varying the
drug/lipid mole ratios from 0.04 to 0.104. However, with any
further increase in the drug/lipid mole ratios up to 0.32, no
differences in the partition coefficient were observed.
2.6. Selection of DPPC liposome formulation for in vivo
studies in rabbit eyes
The data is based on the vesicle storage stability, DSC analysis,
drug partition coefficient and daily dose requirement. A liposomal
formulation of drug/lipid mole ratio of 0.104 was chosen to study
the IOP lowering effect in the rabbit eye, since the current eye
drop administration of XalatanH amounts approximately to
1.5 mg/drop/day [39].
In the sub-conjunctival administration of the liposomal
latanoprost, we wanted to target a similar dose/day sustained
for at least 10 days, assuming a subconjunctival injection volume
of 100 mL. The in vitro release rate (per day) is plotted for two
candidate formulations of DPPC-latanoprost, at drug/lipid mole
ratios of 0.04 and 0.104, in Figure 5 shown for comparison with
the daily dose of XalatanH eye drop. Although the drug/lipid mole
ratio of 0.04 matches the eye drop, its daily rate dips below
XalatanH beyond Day 5, and hence, is unsuitable for sustained
delivery. Thus, we opted to use the DPPC-latanoprost formulation
at a drug/lipid mole ratio of 0.104 for the rabbit study, even
though it demonstrated a higher initial burst release in vitro.
2.7. Topically applied liposomal formulation
We also considered topical administration for the DPPC-
latanoprost formulation, mimicking the eye drop administration of
XalatanH. However, IOP measurement in all the rabbits did not
show any IOP reduction (data not reported) compared to the
XalatanH eye drop. This shows that latanoprost loaded neutral
DPPC liposomal formulation once applied topically cannot enter
through corneal epithelium. This mode of administration of the
liposomal formulation was not considered further and only the
Table 2. Drug loading values before and after synthesis of
liposome vesicles.
Drug: Lipid mole ratio
Initial Final Literature
0.030 0.04460.001 0.02 with ibuprofen in DPPC: Chol [35]
0.065 0.07360.002 ----
0.086 0.10460.020 ----
0.114 0.14060.020 ----
0.143 0.18060.030 ----
0.170 0.37060.050 0.29 with aryl-imidazole (ML220) in DSPC-PEG [40]
doi:10.1371/journal.pone.0024513.t002
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rabbit studies.
2.8. Effects of intraocular pressure from subconjunctival
injection of latanoprost/liposomal formulation
The baseline IOP was 13.660.3 mmHg for all 23 rabbits and
there was no significant difference between all 3 groups (P=0.81)
evaluated. We found a significantly higher mean reduction of IOP
in the subconjunctival latanoprost-loaded liposome (group B)
compared to topical latanoprost eye drop (group A). At 30 days
IOP reduced by 3.060.17 mmHg in group B versus
1.660.18 mmHg in group A (P,0.001) and at 80 days the IOP
reduced by 3.560.60 vs. 2.360.61 mmHg respectively (P,0.001)
(Figure 6).
2.9. Subconjunctival injection of latanoprost/liposome
formulation
We recorded the clinical effect of injecting the liposome
formulation on conjunctival vascularity shortly after administering
the subconjunctival injection and at Day 30 in each treatment
group. No significant increase in conjunctival vascularity in any of
the eyes from the 3 groups was noted. Furthermore, we did not
observe any complications such as conjunctival infection, ulcera-
tion or anterior chamber inflammation on slit-lamp examination
(Figure 7A). The surrounding conjunctiva was white and the
eyelids did not show any signs of swelling or inflammation. Finally,
ASOCT scans confirmed the subconjunctival placement of the
injected liposomes in the superior temporal aspect of each rabbit
eye (Figure 7B). Subsequent ASOCT scans did not reveal any
abnormal conjunctival scarring or scleral thickening at the
injection sites, thus supporting the slit lamp observations.
2.10. Histology
The surrounding conjunctival tissue did not reveal any
significant inflammation or fibrosis on histological examination
of all the enucleated eyes. Sirius red polarizing microscopy of
collagen fibers also revealed no significant increase in the amount
of fibrosis in all 3 groups (Figure 8).
Discussion
It is now recognized that there is a medical need for sustained
delivery of eye drops needed for chronic diseases such as
glaucoma. We selected one such agent, a prostaglandin derivative,
latanoprost for incorporation into liposomes for sustained delivery.
Table 3. Size measurement of liposome formulation (varying d/l mole ratio) during storage at 4uC and after in vitro drug release in
PBS buffer (pH 7.4) at 37uC.
Size measurement, nm (PDI)
Latanoprost/DPPC
Liposome (actual) drug/
lipid mole ratio) W0 W2 W4 W8 W16
After in vitro drug
release
0.00 82(0.05) 93(0.06) ---- 91(0.06) 92(0.06) 93(0.06)
0.04 86(0.05) 89 102(0.06) 104(0.06) 104(0.06) 110(0.06)
0.07 111(0.07) 89(0.06) 98(0.06) 100(0.06) ---- ----
0.10 109(0.08) 105(0.10) 105(0.10) ---- 110(0.10) 150(0.1)
0.14 78(0.06) 93(0.06) 93(0.08) 101(0.08) 117(0.10) 145(0.12)
0.18 194(0.10) 210(0.10) 210(0.10) — 310(0.20) 442(0.20)
0.37 118(0.10) 93(0.10) 93(0.20) 1015(0.3) 1176(0.30) 2020(0.80)
doi:10.1371/journal.pone.0024513.t003
Figure 1. Malvern Zeta sizer analysis of drug loaded liposome. The values reported are after 12 weeks of storage at 4uC with drug/lipid mole
ratio (size, nm) (a) 0.044 (63610), (b) 0.11 (90630), (c) 0.18 (200680) and (d) 0.37 (12506200). Size measurement reported here are mean of three
batches and the standard deviations (6) are expressed inside bracket.
doi:10.1371/journal.pone.0024513.g001
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DPPC liposomes. The lipophilic nature of latanoprost with a
logP=4.4 (Data from SRC PhysProp Database) clearly indicates
that the loaded drug resides predominantly in the bilayer.
However, a measurable amount of latanoprost also resides in the
aqueous phase outside of the liposomes. This is reflected in the
measured partition coefficients, which vary from about 12 to 6,
depending on initial drug loading. These numbers translate to
about 8% and 17% ‘‘free drug’’ outside of the liposomes. Free
drug removal from the formulation was not carried out, as
removal requires a fairly lengthy process. Removal of free
lipophilic drug (ibuprofen) from liposomal formulation is also not
routinely performed [35]. Therefore, all the experiments and
analyses were based on the formulation obtained after extrusion
step, which contains mostly liposome-incorporated latanoprost,
with about 17% free drug in the case of the 0.104 drug/lipid mole
ratio formulation.
The drug/lipid mole ratio estimated here is nearly 3–5 times
more than earlier reported lipophilic drugs eg. Ibuprofen [35] and
Figure 2. In vitro dialysis study of latanoprost from drug
loaded DPPC LUVs after extrusion. Cumulative latanoprost release
(%) from DPPC LUVs loaded with varying amount of drug/lipid mole
ratios: (a) 0.044, (b) 0.11, (c) 0.14, (d) 0.18 and (e) 0.37. Each value is the
mean (standard deviations is plotted as error bars, which are always less
than 3% for nearly all batches) of the results obtained from at least
three independent experiments.
doi:10.1371/journal.pone.0024513.g002
Figure 3. DSC analysis of pure and latanoprost loaded DPPC MLVs. The liposome was made by PBS buffer hydration of anhydrous drug-lipid
layer. 10 ml of the liposomal formulation (100 mg/ml) was heated at 1uC/min between 220uCt o6 5 uC. Three heating and two cooling cycles were
carried out with each sample and the last reproducible heating cycle was considered for analysis. The drug/lipid mole ratios and their corresponding
enthalpy change during transition are reported within parentheses (a) 0.0 (18.9 J/g), (b) 0.03 (8.7 J/g), (c) 0.086 (8.1 J/g), (d) 0.114 (5.2 J/g) and (e) 0.14
(1.6 J/g).
doi:10.1371/journal.pone.0024513.g003
Figure 4. Partition coefficient of latanoprost. Partition coefficient
of latanoprost was calculated by taking the ratio of drug concentrations
in lipid bilayer and the aqueous buffer. The drugs to lipid loading
concentrations (mole ratios) are 0.04, 0.104, 0.14, 0.18, and 0.32 in DPPC.
Each partition coefficient value was obtained from the mean of three
MLV formulations made and the standard deviations are reported in
error bars.
doi:10.1371/journal.pone.0024513.g004
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drug aryl- imidazole compound (ML220) loaded in DSPE-PEG
liposome have a reported 3 weeks of stability at the incubation
temperature (37uC) [40].
Storage stability analysis shows that vesicles with no drug or
with lower drug amounts (drug/lipid mole ratio of 0.14) remain
unaffected. When the quantity of drug is increased to drug/lipid
mole ratio of 0.18 and above, destabilization is noted from 4 weeks
onwards. Size analysis after drug release at 37uC in PBS buffer
shows similar behavior to that during storage. The destabilization
is magnified at the higher drug/lipid formulations. A possible
explanation for the destabilization of the vesicles with increase in
loading lies in the interactions of latanoprost with the bilayer acyl/
phosphate head group of DPPC liposomes. Latanoprost molecules
(at high loading) could possibly weaken the hydrogen bonding
between the phosphate head groups that hold vesicle together
[41]. However; this postulate remains to be confirmed with
suitable studies. Thus, vesicles with a lesser amount of drug (till
drug/lipid mole ratio of 0.14) are stable for at least one month.
In general, we noted drug release rate to increase with an
increase in drug/lipid mole ratios. There are currently no
accepted models for the release of drugs from liposomes. If we
treat the liposomal carriers as ‘‘monolithic matrices’’ and assume
mainly diffusional release of drug, then for either dissolved or
dispersed drug, we expect a decrease in rate with loading rather
than an increase [42]. However, we observed no dependence on
loading when the drug/lipid ratios ranged from 0.04 to 0.11, but
an increase in rate with loading for drug/lipid mole ratios .0.11
was seen. This increase is attributable to a more ‘‘destabilized’’
vesicle in terms of size increase during the release study (Table 3),
which implies the creation of a larger vesicle bilayer more
permeable to diffusion. Beyond drug/lipid ratios of 0.11, the
latanoprost appears to be loaded beyond its saturation limit in the
bilayer, and as a consequence, the metastable bilayer changes in
size over time and being destabilized.
The thermal stability (DSC) analysis of drug loaded DPPC
liposome indicates peak broadening with drug loading. The sharp
transitions (pre- and main) disappear (Figure 3) with drug
incorporation. Mannock et al [38] reported peak broadening
due to incorporation of cholesterol in DPPC bilayer and
attributed this to probable loss of crystalline nature of DPPC
lipids. However, unlike cholesterol incorporation into DPPC,
which leads to a drop in transition temperature, latanoprost
loaded DPPC liposomes behave differently. At the release
condition, the bilayer is expected to remain in the rigid gel
phase (high crystalline) for DPPC (Tc=41.1uC). With lower
amount of drug/lipid mole ratio there is an increase in transition
temperature from 41.1 for drug/lipid=0 to 44.8 for drug/
lipid=0.04 and 46.6 with drug/lipid=0.086. Recently, Bolean
et al [43] have reported a similar peak broadening and rise in
transition temperature with higher incorporation of cholesterol in
DPPC liposome. At high molar concentrations, cholesterol exists
as a sterol rich domain (also called ‘‘non-cooperative zone’’)
leading to peak broadening and a shift towards higher
temperature [44]. This domain formation is also reflected in an
increase in vesicle diameter which is similar to our observation
with higher mole % of latanoprost in DPPC (Table 3). DPPC
lipid volume was estimated [45] to be ,1200 A ˚ 3/molecule (of
which ,900 A ˚ 3 is for acyl chains and rest ,300 A ˚ 3 for
phosphate head group) while the latanoprost molecule has an
approximate volume of ,500 A ˚ 3 based on molecular dynamic
calculations [46]. With increased proportion of latanoprost,
gradually the lipid-latanoprost interaction increases due to bilayer
space constraint, which may lead to an increase in transition
temperature of the binary system [43]. However, the existence of
a maximum in the transition temperature (with drug/lipid mole
ratio) requires further investigation. The enthalpy change
(Figure 3) at the main transition with pure DPPC (18.9 J/g)
gradually decreases to 8.7, 8.1, 5.2, 1.6 J/g respectively with
increase in drug/lipid mole ratios at 0.03(b), 0.086 (c), 0.114 (d),
0.14 (e). This also supports the postulated latanoprost-lipid
interaction that renders the bilayer more fluidic or disordered
[44].
Partition coefficient analysis indicates a drop in drug distribu-
tion between the lipid bilayer and the continuous phase, with
increased drug loading. After the initial decrease (from about 11 to
about 6), the partition coefficient remains unaltered. The partition
coefficient gives an estimate of the drug distribution between the
Figure 5. Latanoprost release rate from 100 ml of DPPC LUVs
with two different drug/lipid mole ratios compared with 1 drop
of commercial XalatanH solution (1.5 mg/drop). In vitro drug
release rate (mg/day) measured from (a) drug/lipid, 0.04 and (b) drug/
lipid, 0.11, (c) commercial eye drop (XalatanH, 1.5 mg/drop). The release
rates are reported based on mean values of at least two batches and
standard deviations are reported in error bars.
doi:10.1371/journal.pone.0024513.g005
Figure 6. Comparison of intraocular pressure (IOP) between
topical latanoprost eyedrop, subconjunctival latanoprost lipo-
some and latanoprost-free blank liposomes. Group A: topical
latanoprost eye drop. Group B: subconjunctival latanoprost liposome.
Group C: latanoprost-free blank liposomes.
doi:10.1371/journal.pone.0024513.g006
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drug incorporation also strongly influences the partition coefficient
value [47].
For smaller drug quantities such as drug/lipid mole ratio of
0.04, the drug molecules prefer to remain in the bilayer as
entrapped drug and the rest as free drug in the buffer. The
accumulation of the drug in the bilayer is limited by the bilayer
area available in the vesicles. Favorable drug-bilayer interactions
could increase this bilayer loading as well. For higher drug loading
amounts, there is a significant amount of the drug existing as free
drug in the continuous buffer phase of the liposomes, as the bilayer
gets saturated with drug molecules. This appears to explain the
decrease seen in the partition coefficient values seen in our study
In vivo studies revealed that a single depot subconjunctival
injection of latanoprost-loaded liposome results in a sustained,
therapeutic lowering of IOP beyond 50 days. The extent of IOP
lowering was significantly better using the liposomal formulation
than free latanoprost administered daily via eye drop, the current
‘standard of treatment’ in glaucoma patients. This is consistent
with our in vitro results that show a sustained release (and a higher
amount released compared to the eye drop) over 10 days, while
maintaining vesicle size and shape. The significant and sustained
reduction of IOP in rabbit eyes is encouraging, and to our
knowledge, there are no other reports that show such a dramatic
improvement in latanoprost sustainability by DPPC liposomes via
subconjunctival injections in an animal eye. We also used slit-lamp
microscopy, histology and imaging techniques such as AS-OCT to
demonstrate that these liposomes appear to be well tolerated in an
animal eye, biocompatible and does not cause any obvious clinical
adverse effects to the ocular tissues with the subconjunctival
injection of the liposomal carrier.
Because of the measured higher initial rate of drug release from
the DPPC formulation, there were concerns about side effects
during initial stages following injection. However, throughout the
duration of our study, we did not detect any obvious effect with the
methods used for clinical monitoring. There was also no residual
drug either in the aqueous or vitreous humor at the end of study. It
is also interesting to note that repeat injections of drug loaded
DPPC liposome treatment did not result in any hyperpigmentation
to the cornea or conjunctiva. Unlike the commercial eye drop
(XalatanH), the present formulation is devoid of any preservatives
such as benzalkonium chloride (BAK), which is thought to be the
root cause of the cornea pigmentation [48]. The short period of
exposure to the drug may also be a reason for the absence of
clinical corneal changes.
3.1. Conclusions
The IOP lowering effect from a single subconjunctival injection
of the reported liposome formulation was sustained for up to 50
days and was comparable to daily administration of eye drops.
The outcomes from our studies report positive and significant
benefits over the commercial eye drop formulation. Subconjunc-
Figure 7. Rabbit eyes condition after subconjunctival injection. Serial slit-lamp microscopy (group A) revealed no significant increase in
vascularity and inflammation of all rabbit eyes (I and II: Day 0 after subconjunctival injection; III and IV: Day 30 after subconjunctival injection). AS-OCT
scans (group B) revealed no abnormal scarring, scleral or conjunctival thinning in all rabbit eyes (Photos I and II). *SC=Liposome injection site;
C=Cornea.
doi:10.1371/journal.pone.0024513.g007
Figure 8. Histology of rabbit eyes. Group A: topical latanoprost eyedrops. Group B: subconjunctival latanoprost liposomes. Group C:
subconjunctival latanoprost-free liposomes. Histology revealed no abnormal scarring or damage to the collagen layers in both H&E stain (Photos I
and II) and Picrosirius red stain (Photos III and IV; Grade 1 for all eyes). S=Sclera; C=Conjunctiva.
doi:10.1371/journal.pone.0024513.g008
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drugs may prove to be a suitably attractive alternative to current
topical eyedrops.
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